(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 47.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Ars Pharmaceuticals's revenue in 2025 is $112,339,000.On average, 4 Wall Street analysts forecast SPRY's revenue for 2025 to be $8,305,365,361, with the lowest SPRY revenue forecast at $7,358,609,053, and the highest SPRY revenue forecast at $9,317,347,052. On average, 4 Wall Street analysts forecast SPRY's revenue for 2026 to be $21,550,071,046, with the lowest SPRY revenue forecast at $15,795,413,443, and the highest SPRY revenue forecast at $24,549,450,374.
In 2027, SPRY is forecast to generate $36,093,651,278 in revenue, with the lowest revenue forecast at $30,236,906,069 and the highest revenue forecast at $40,746,098,745.